Oncodesign Precision Medicine
Biotech specialized in precision medicine, our mission is to bring innovative therapeutic and diagnostic solutions to treat resistant and metastasis cancer.. .
Biotech specialized in precision medicine, our mission is to bring innovative therapeutic and diagnostic solutions to treat resistant and metastasis cancer.. .
Perfect, your title contains between 10 and 70 characters.
Great, your meta description contains between 70 and 160 characters.
We found 12 images on this web page. 2 alt attributes are empty or missing. Add alternative text so that search engines can better understand the content of your images.
Good, this page's ratio of text to HTML code is higher than 15, but lower than 25 percent.
Perfect, no Flash content has been detected on this page.
Great, there are no Iframes detected on this page.
locale | en_GB |
---|---|
locale:alternate | fr_FR |
type | website |
title | Oncodesign Precision Medicine |
description | Biotech specialized in precision medicine, our mission is to bring innovative therapeutic and diagnostic solutions to treat resistant and metastasis cancer. |
url | http://www.oncodesign.com/ |
site_name | Oncodesign Precision Medicine |
image | https://www.oncodesign.com/wp-content/uploads/2022/09/oncodesign-pm-home-intro.png |
image:width | 599 |
image:height | 493 |
image:type | image/png |
Internal Links 95.83%
External Links [DoFollow 4.17%]
External Links [NoFollow 0%]
Anchor | Link | Type | Relationships |
---|---|---|---|
Learn more | https://oncodesign-services.com/ | External | DoFollow |
Our pipeline | https://oncodesign.com/our-pipeline/ | Internal | DoFollow |
Partnering | https://oncodesign.com/our-pipeline/partnering/ | Internal | DoFollow |
Our innovation technologies | https://oncodesign.com/our-innovation-technologies/ | Internal | DoFollow |
OncoSNIPER | https://oncodesign.com/our-innovation-technologies/oncosniper/ | Internal | DoFollow |
Nanocyclix | https://oncodesign.com/our-innovation-technologies/nanocyclix/ | Internal | DoFollow |
PROMETHE | https://oncodesign.com/our-innovation-technologies/theranostics/ | Internal | DoFollow |
Investors | https://oncodesign.com/investors/ | Internal | DoFollow |
Message from the chairman | https://oncodesign.com/investors/message-from-the-chairman/ | Internal | DoFollow |
Regulated information [FR] | https://oncodesign.com/investors/regulated-information/ | Internal | DoFollow |
Press Release | https://oncodesign.com/press-release/ | Internal | DoFollow |
General Meetings [FR] | https://oncodesign.com/fr/investisseurs/assemblee-generale/ | Internal | DoFollow |
About us | https://oncodesign.com/about-us/ | Internal | DoFollow |
Latest news | https://oncodesign.com/about-us/news/ | Internal | DoFollow |
Our history | https://oncodesign.com/about-us/our-history/ | Internal | DoFollow |
Management | https://oncodesign.com/fr/a-propos/management-2/ | Internal | DoFollow |
Our HR policy | https://oncodesign.com/about-us/careers/ | Internal | DoFollow |
Our CSR approach | https://oncodesign.com/about-us/our-csr-approach/ | Internal | DoFollow |
FederAidd | https://oncodesign.com/about-us/federaidd/ | Internal | DoFollow |
Contact us | https://oncodesign.com/contact-us/ | Internal | DoFollow |
OPM announces a 6 million euros bank financing | https://oncodesign.com/opm-announces-a-6-million-euros-bank-financing/ | Internal | DoFollow |
OPM announces positive interim results of its Phase 1 study | https://oncodesign.com/opm-announces-positive-interim-results-of-its-phas | Internal | DoFollow |
Legal notice | https://oncodesign.com/legal-notice/ | Internal | DoFollow |
Personal data policy | https://oncodesign.com/personal-data-policy/ | Internal | DoFollow |
Keyword | Content | Title | Keywords | Description | Headings |
---|---|---|---|---|---|
news | 5 | ||||
therapeutic | 5 | ||||
opm | 4 | ||||
learn | 4 | ||||
more | 4 | ||||
innovative | 3 | ||||
pipeline | 3 | ||||
read | 3 | ||||
innovation | 3 | ||||
technologies | 3 | ||||
oncodesign | 3 | ||||
investors | 3 |
14 Length
Perfect. Your declared charset is UTF-8.
Good. Your declared language is EN.
Great! We haven't found deprecated HTML tags in your HTML.
Great, your website has a favicon.
Great no email address has been found in plain text!
This page does not take advantage of Dublin Core.
We could not find a Print-Friendly CSS.
oncodesign precision medicine, to find the best therapeutic path, our pipeline, our technologies, opm announces a 6 million euros bank financing, opm announces positive interim results of its phase 1 study, newsletter, attention javascript est désactivé sur votre poste. ce site nécessite l'activation de javascript pour fonctionner correctement., our science, news, learn, model, promethe, explore, discovery, innovation, oncodesign, covering, programs, oncosniper, highly, opportunities, policy, october, technologies, newsletter, medicine, technological, activities, also, opm, innovative, services, science, javascript, more, news, pipeline, best--class, attention, precision, latest, shared, dedicated, nanocyclix, drug, goals, first--class, read, solutions, several, patients, all, therapeutic, areas, cro, benefit, patient, investors, announces, oncodesign.com.